Immunovaccine Researchers to Present New Preclinical Data at AACR Annual Meeting 2018
March 19 2018 - 5:05PM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that the Company will
present research on the anti-cancer potential of its proprietary T
cell-activating platform at the American Association for Cancer
Research (AACR) Annual Meeting 2018. Presentations will include
preclinical analysis of a triple combination immunotherapy stemming
from the Company’s ongoing collaboration with Incyte Corporation,
as well as the heightened effects of its novel delivery platform on
T cell activation.
“This research highlights some of the unique features of our
proprietary technology,” said Marianne Stanford, PhD, Vice
President, Research, Immunovaccine. “From improving T cell
infiltration to support heightened efficacy in combination with
other immunotherapies, to enabling a broader range of peptides to
act together to improve the potential of anti-cancer therapies, we
believe that the novel mechanism of action underscoring our
pipeline has a very broad range applications for the immunotherapy
landscape. We look forward to continued collaboration with our
partners to further this work.”
Details of Immunovaccine’s AACR 2018 presentations are as
follows:
Abstract Number: 1761Author:
MacKay, A. et al. Title: “Combination of a T cell
activating immunotherapy with immune modulators alters the tumour
microenvironment and promotes more effective tumour control in
preclinical models"Date: Monday Apr 16,
2018Time: 8:00 a.m. - 12:00 p.m.
CTLocation: McCormick Place South, Exhibit Hall A,
Section 33
Abstract Number:
1726Author: Kaliaperumal, V. et
al.Title: “A novel delivery platform containing up
to 14 neoantigens can induce robust immune responses in a single
formulation.”Date: Monday Apr 16, 2018
Time: 8:00 a.m. - 12:00 p.m.
CTLocation: McCormick Place South, Exhibit Hall A,
Section 32
The AACR Annual Meeting 2018 takes place from April 14 to 18 at
the McCormick Place North/South in Chicago. Meeting abstracts are
available at AACR's website.
About Immunovaccine Immunovaccine
Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology provides controlled and
prolonged exposure to a broad range of immunogenic stimuli.
Immunovaccine has advanced two T cell-activating therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing its
lead cancer therapy, DPX-Survivac, as a combination therapy in
ovarian cancer. The Company is also exploring additional
applications of its platform, including DPX-RSV, an innovative
vaccine candidate for respiratory syncytial virus (RSV), which has
recently completed a Phase 1 clinical
trial. Immunovaccine also has ongoing research projects
in malaria and the Zika virus. Connect
at www.imvaccine.com.
Immunovaccine Forward-Looking Statements This
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of them will be achieved. Actual results
may differ materially from those set forth in this press release
due to risks affecting the Company, including access to capital,
the completion of clinical trials and receipt of all regulatory
approvals. Immunovaccine Inc. assumes no responsibility
to update forward-looking statements in this press release except
as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown Inc. T:
(312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572
E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024